Can Rigel (RIGL) Climb 69.55% to Reach the Level Wall Street Analysts Expect?

Group 1 - Rigel Pharmaceuticals (RIGL) closed at $19.9, with a 6.4% gain over the past four weeks, and a mean price target of $33.74 suggests a 69.6% upside potential [1] - The average price target ranges from a low of $20.45 to a high of $57.00, with a standard deviation of $17.29, indicating variability among analysts' estimates [2] - Analysts show strong agreement on RIGL's ability to report better earnings, with a positive trend in earnings estimate revisions correlating with potential stock upside [4][11] Group 2 - Over the last 30 days, the Zacks Consensus Estimate for RIGL's current year earnings has increased by 19%, with no negative revisions [12] - RIGL holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimates [13] - While the consensus price target may not be a reliable indicator of RIGL's potential gain, it does provide a directional guide for price movement [14]